Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

Table 4

Randomized phase III trials with nab-paclitaxel in aNSCLC.

	Arms	Pts	ORR			Median; PFS; (MO); 𝑃=  <.214	Median; OS; (MO); 𝑃=  <.271	AEs grade III*-IV** (%) 𝑃=  <.001
			Median; (%); 𝑃=.005	SQ; (%); 𝑃=  <.001	NSQ; (%); 𝑃=  <.80			Neutropenia	Thrombocytopenia	Fatigue	Anemia
Socinski et al., 2012 [49]; (first line)	Nab-paclitaxel 100 mg/m^2	521	33	41	26	6.3	12.1	33*	13*	4*	22*
	Carboplatin AUC6 q3w							14**	5**	<1**	5**
	Paclitaxel 200 mg/m^2	531	25	24	25	5.8	11.1	32*	7*	6*	6*
	Carboplatin AUC6 q3w							26**	2**	<1**	<1**

P: P value; nd: not done; sq: squamous histology of NSCLC; nsq: non squamous histology of NSCLC; AEs: adverse events; ORR: overall responce rate; RR: response rate; PFS: progression-free survival; OS: overall survival.